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Anal cancers are rare tumours; however, the incidence is increasing in both men and women. Changing trends in sexual behaviour,
smoking, and infection with the human papillomavirus are thought to be responsible for the increase. Patients with metastatic
disease have a poor prognosis, with 5-year median overall survival rates of 10% in men and 20% in women. The standard systemic
treatment of metastatic disease remains cisplatin and 5-ﬂuorouracil, and aside from several non-randomised small phase II trials
there has been no real progress over the past two decades. Based on the eﬃcacy of cetuximab in squamous cell carcinomas from
otherprimarysites,thereappearstobeclinicalrationaleforevaluationofanti-epidermalgrowthfactorinhibitorsinanalsquamous
cell carcinoma. In order to facilitate research and implement more eﬀective treatment strategies international collaboration in
clinical trials incorporating tissue collection for biomarkers is essential.
1.Introduction
Anal cancers are rare tumours; in the UK there are approxi-
mately 900–1000 cases diagnosed per year, and in the USA
they account for 1-2% of all gastrointestinal cancers [1].
However, the incidence is increasing in certain populations
with high-risk behaviour and in those with the human im-
munodeﬁciency virus (HIV) [2, 3]. One of the most well-
known risk factors is the human papillomavirus (HPV),
particularly HPV type 16, which is present in approximately
80% of patients diagnosed with anal cancer [4]. Other risk
factors include smoking, increased number of sexual part-
ners, sexually transmitted infections, a history of vaginal or
cervical malignancy, other conditions associated with lower-
ed immunity, for example, transplant recipients and those
with anal inﬂammatory conditions. Eighty percent of anal
cancers are squamous cell carcinomas (SCCs); other rarer
types of histology include adenocarcinoma, basal cell carci-
noma, and melanoma [5].
The majority of cases present with early-stage localized
disease. In this setting combined modality treatment with
chemoradiation remains the standard of care allowing
sphincter sparing whilst reserving surgery for those with
persistentorrecurrentdiseasefollowingtreatment[6].Based
on the available data a radiation dose of at least 45–50Gy in
combination with MMC and 5FU is currently the most com-
monly employed regimen [7–10].
Early-stage disease (T1/T2 N0) is associated with a good
prognosis [11]. However, the ﬁve-year overall survival for
those with more locally advanced disease ranges from 40–
80% and 10 to 20% of patients will develop distant meta-
stases following combined modality treatment [10, 12]. The
prognosis for patients with distant metastases is generally
poor, although documented median survival rates vary from
8 to 34 months. The SEER database reports 5-year survival
rates of 10% in men and 20% in women between 1973 and
2000 [2, 11].
This paper reviews the existing literature regarding sys-
temic treatment of patients with metastatic squamous cell
carcinoma of the anus and explores potential future direc-
tions.
2. Trials of Systemic Chemotherapy
It is striking that in anal cancer only six randomized
trials have been performed over the last three decades. In2 ISRN Oncology
Table 1: Phase II chemotherapy trials of metastatic squamous cell carcinoma of the anus.
Author Number of patients Agents Response rate Median PFS (months) OS (months)
Wilking et al. [13]1 5
Vincristine, bleomycin,
and high-dose
methotrexate
3/12 (25%) 2 NR
Hainsworth et al.
[14]
60
(7 with anal cancer)
Paclitaxel, carboplatin,
and infusional 5FU
65% overall
4/7 (57%)
anal patients
35 overall
(26 anal patients) NR
Jhawer et al. [15]2 0
Mitomycin C,
adriamycin, cisplatin,
and bleomycin-CCNU
12/20 (60%) 8 15
Table 2: Case reports of single-agent chemotherapy in metastatic anal squamous cell carcinoma.
Author Number of patients Agent Response PFS/duration of response (months) OS
Evans et al. [16] 1 Carboplatin Partial 9 NR
Fisher et al. [17]1 Doxorubicin and
cis-dichlorodiammineplatinum Major NR NR
Zimm and
Wampler [18] 1 Semustine Partial 15 NR
Golub et al. [19]3 T I P Complete
(3/3) 4,6,36 NR
Grifalchi et al. [20] 1 Irinotecan Partial NR NR
the metastatic setting the available evidence is based on
small phase II trials (Table 1), retrospective series, and case
reports (Table 2), and there have been no prospective phase
III studies or meta-analyses.
The most plausible explanation is simply the relative
rarity of the disease and the small number of patients treated
at each centre. Unfortunately anal cancer still suﬀers from a
social stigma with an “embarrassing location” and the asso-
ciation with sexually transmitted infections and HIV. There
has certainly not been the same degree of public interest
a n ds u p p o r tf o ra n a lc a n c e ra sd e m o n s t r a t e di no t h e rs o l i d
tumours, for example, breast or testicular cancer.
Systemic chemotherapy remains the mainstay of treat-
ment for patient with metastatic disease. The choice of che-
motherapy is inﬂuenced by any previous treatment the pa-
tient received for early disease, the disease-free interval, and
the patient’s performance status and wishes. The National
Comprehensive Cancer Network (NCCN) Guidelines cur-
rently recommend cisplatin and 5FU chemotherapy as ﬁrst-
line treatment of metastatic squamous cell carcinoma (SCC)
[21]. This is largely based on a study of 19 patients treated
with cisplatin 100mg/m2 and infusional 5FU 1gm/m2/day
over 5 days with a 66% response rate; there was 1 complete
response and 11 partial responses in addition to 4 patients
with stable disease. The actuarial survival was 62.2% at 1
year and 32.2% at 5 years, and the median survival was 34.5
months [22]. There have also been a number of case reports
demonstrating a beneﬁt with the cisplatin/5FU combination
[23–25].
Recently the oral ﬂuoropyrimidine capecitabine has been
substituted for 5FU in a number of solid tumours, and,
extrapolating from this data, many centres now use capeci-
tabinewithcisplatinratherthan5FU[26].Thishasanumber
of advantages for patients, including ease of administration
and avoidance of indwelling lines and their associated com-
plications [27].
MMC and 5FU are an alternative ﬁrst line combination
although there is less evidence to suggest an impact on sur-
vival. In a retrospective series, three of eight patients treated
with MMC and 5FU had a response to treatment in terms of
decreaseintumoursize,reductioninpain,andimprovement
in performance status [28].
In an early phase II study, vincristine, bleomycin, and
high-dose methotrexate were given to 15 patients; three out
of the twelve patients with measurable disease (25%) had
objective responses of 1-, 2-, and 5-month duration. How-
ever ﬁve of the ﬁfteen patients had severe or life-threaten-
ing complications as a result of this treatment regimen and
subsequently the regimen was deemed too toxic to warrant
further evaluation [13].
In a single arm trial of twenty patients treated with mito-
mycin C, adriamycin, cisplatin, and bleomycin-CCNU, 12
(60%) patients had a partial response and no complete res-
ponses were observed. The median survival in this study was
15 months (95% CI 6–20 months), and the median time to
progression or death was 8 months (95% CI 4–9 months).
Toxicity was not insigniﬁcant, and although these side eﬀects
were managed without sequelae, the combination has not
been explored in a phase III trial due to toxicity [15].
The most encouraging results have been demonstrated
in a phase II single arm study of paclitaxel, carboplatin,
and continuous infusional 5FU in patients with advanced
squamous carcinomas (n = 60) from multiple primary sites,
givenﬁrstorsecondline.SevenpatientswithSCCoftheanus
were included, of these four responded, two of whom had a
complete response. The patients with a complete responseISRN Oncology 3
then received consolidation radiotherapy to the primary
tumour. The median duration of response in the anal sub-
group was 26 months (range 10–63+) [14]. Although most
patients were able to tolerate full doses of all three drugs,
gastrointestinal toxicities (mucositis and diarrhoea) were
responsible for most dose reductions. Interestingly substan-
tial activity of this three-drug combination was demonstrat-
ed across all tumour types in the trial, with an overall com-
p l e t er e s p o n s er a t eo f2 5 % .
There have been several single case reports or series eval-
uating alternative monotherapy or combination chemother-
apyregimens.Thesedataarelimitedbyrelativelysmallnum-
bers and lack of prospective validation. The three-drug re-
gimen, paclitaxel, ifosfamide and cisplatin (TIP), has been
used in head and neck cancer and cervical squamous cell
carcinomas, and a recent case series reported three patients
with metastatic anal SCC treated with TIP. All three patients
had a complete response with disease-free intervals of 4, 6,
and 36 months, all required prophylactic GCSF support dur-
ing their treatment [19].
3. LocalisedTherapies
The liver is the most common site of metastases, and the
role of regional therapy has been explored in a multicentre
analysis of 52 patients with squamous cell carcinomas, 27
of whom had metastatic anal cancer. Patients underwent
hepatic resection (n = 47), radiofrequency ablation (n = 3),
or both (n = 2), and the majority had received systemic ther-
apy prior to resection. When the analysis was restricted to
the 27 patients with metastatic anal cancer, the median dis-
ease-free and overall survival durations were 9.6 and 22.3
months, respectively [32]. These data suggest that there may
be a subset of patients with isolated hepatic metastases who
may beneﬁt from resection, but selection criteria are as yet
undeﬁnedandmetastasectomyisnotcurrentlystandardpra-
ctice.
Palliative surgery for the primary lesion in those with
metastatic disease and symptomatic local disease is an op-
tion.Forthosewithsigniﬁcantcomorbiditiesunabletotoler-
ate systemic chemotherapy or surgery palliative radiotherapy
alone is an alternative local therapy. Eﬀective palliation can
be achieved with a dose of 45–54Gy in 25–30 fractions; how-
ever, alternative shorter or hypofractionated regimens such
as 30Gy in 10 fractions or 6Gy/week for 5-6 weeks may be
more appropriate for frailer patients.
The role of a shortened course of chemoradiation (30Gy
in 10 fractions with concurrent 5FU) has also been evaluated
in elderly patients, demonstrating high rates of local control
[33].
4.The Role of EGFR-TargetedTherapies in
Anal Cancer
Squamous cell carcinoma of the anal canal has a number of
similarities to cervical and head and neck squamous tum-
ours, in terms of histology, a strong causative association
with HPV infection and relative radiosensitivity. Squamous
cell carcinoma of the anus, in common with cervical and
head and neck squamous tumours, regularly overexpresses
the epidermal growth factor receptor (EGFR). In a large
cohort of invasive anal SCC tissue samples (n = 101) im-
munohistochemistry analysis of EGFR demonstrated that
the majority of invasive anal SCCs overexpressed EGFR. Of
the 101 patient biopsies available, 82 samples had suﬃcient
material for interpretation of these 72/82 (90%) stained
positive for EGFR, while 41/82 (50%) samples displayed at
least moderate to strong staining [34]. Similar results have
been demonstrated in a number of smaller studies, with
range of EGFR overexpression of 55–100% [35, 36]. Inter-
estingly EGFR gene ampliﬁcation was not observed in these
studies suggesting that overexpression occurs via mecha-
nisms other than gene ampliﬁcation.
Therearedatatosuggestacorrelationbetweenoncogenic
HPV and EGFR expression. In a study by Walker et al.
96% of invasive HPV-infected anal SCCs displayed strong
membrane immunoreactivity to EGFR expression. It is also
thought that HIV-positive status contributes in augmenting
EGFR expression levels that are involved in carcinogenesis
[37].
Mutations in the downstream eﬀectors KRAS and BRAF,
which are responsible for a lack of response to anti-EGFR
antibodies in colorectal adenocarcinomas, appear rarer in
anal tumours [38]. In a study of 95 tumour biopsies from
squamous cell anal cancers, the tumours lacked the common
KRAS and EGFR mutations. Only three samples had an
EGFR exon 21 mutation and none had KRAS mutations. In
a smaller series of three tumours that expressed EGFR, none
hadamutationinKRASc odon12or13[39].Theanti-EGFR
monoclonal antibody cetuximab has demonstrated eﬃcacy
in head and neck squamous cell tumours when admini-
stered concomitantly with radiotherapy [40]. In a case series
of 7 heavily pretreated anal cancer patients, cetuximab was
givenincombinationwithirinotecan.Incontrasttoprevious
studies, KRAS mutations were demonstrated in a number of
patients in this case series. Response (deﬁned as partial or
minor) was seen in the KRAS wild type patients (n = 5)
with no response demonstrated in the patients with KRAS
mutations (n = 2) [30]. These ﬁndings correlate with the
results of two case reports of patients who achieved an
excellent response to treatment with irinotecan and cetux-
imab having previously failed irinotecan [29, 31]( Table 3).
These data in a relatively small patient population and
the presence of EGFR overexpression in anal SCC suggest
that the combination of irinotecan and cetuximab warrants
further evaluation. An alternative combination of paclitaxel
withcetuximabhasbeenevaluatedinanumberofsquamous
cellcarcinomaswithencouragingresults.InaphaseIItrialof
patients with stage IV non-small-cell lung cancer (NSCLC),
a 3-weekly combination of paclitaxel (100mg/m2/week for 3
weeks), carboplatin (area under curve = 6), and cetuximab
(400mg/m2 loading dose followed by 250mg/m2/week) was
safe and well tolerated; the response rate was 57% with
an overall survival of 13.8 months [41]. A weekly regimen
of paclitaxel (80mg/m2/week) with cetuximab (400mg/m2
loading dose followed by 250mg/m2/week) was evaluated
in a phase II study in squamous cell carcinoma of the head
and neck; the combination was well tolerated with an overall4 ISRN Oncology
Table 3: Studies of cetuximab in metastatic anal squamous cell carcinoma.
Author Number of patients Agent Response PFS/duration of response OS
De Dosso et al.
[29] 1 Irinotecan + cetuximab Partial Patient died of PE on treatment NR
Lukan et al. [30] 7 Irinotecan + cetuximab 5/7 response∗ (3 partial, 1
minor, and 1 stable) 6N R
Phan and Hoﬀ
[31] 1 Irinotecan + cetuximab Partial NR NR
∗All ﬁve that responded were KRAS wild type.
response rate of 71% and disease control rate of 88% [42].
In light of similarities in the histology and pathogenesis
between squamous cell carcinomas, these results suggest that
the combination of paclitaxel and cetuximab is worthy of ex-
ploration in anal cancer.
5. Prognostic Factors
Poor prognostic factors include male sex, age over 65 years,
more advanced T stage, nodal involvement, or poorly diﬀer-
entiated histology. In a review of prognostic factors derived
from a prospective database male sex and clinically node
positive disease were conﬁrmed as poor prognostic factors
for both disease-free and overall survival [43]. Black African
Americans have worse outcomes than white American
patients. Anal cancer is not an AIDS-deﬁning illness; how-
ever, patients with HIV appear to have lower overall survival
rates compared to HIV-negative patients [44].
A number of potential prognostic biomarkers have been
evaluated in small studies; the tumour suppressor genes p53
and p21 are the only markers found to have an association
withoutcomeinmorethanonestudy[45].Eventheseresults
are not consistent; p53 was associated with worse outcome
in two studies but no association was demonstrated in six
others [46–48]. Variability in methodology and small patient
numbers may explain the discordance results [49, 50].
Alternative potential markers including apoptotic regulators
( B c l 2B A X ,a n dN F - K B ) ,E G F R ,c y c l i n sA ,D ,a n dE ,m a r k e r s
of proliferation (ki67, and MiBL), and angiogenic factors
have also been evaluated in small studies. None of the results
have been replicated in larger studies, and as yet there is no
biomarker with the ability to predict outcome in this disease.
6. Conclusions
There have been very few developments in the treatment of
metastatic disease for some time and currently there are no
ongoing phase II or III trials speciﬁcally for anal cancer. In
the era of Personalized medicine it would appear time for a
shift in the treatment paradigm for patients with metastatic
anal cancer. New experimental regimens may achieve bet-
ter results and novel strategies of combination cytotoxic
platforms with anti-EGFR targeted agent may lead to im-
proved eﬃcacy. In order to facilitate research and implement
more eﬀective treatment strategies clinical trials incorporat-
ing tissue collection for biomarkers are essential. Interna-
tional collaboration in global clinical trials is imperative and
could improve outcomes in this setting.
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